Loading...
Header Logo
Keywords
Last Name
Institution

SHIAO-PEI WEATHERS

TitleAssistant Professor
InstitutionMD Anderson
DepartmentNeuro-Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer. 2019 May; 112:83-93. PMID: 30951926.
      View in: PubMed
    2. Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF. Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther. 2019 May; 18(5):991-1000. PMID: 30926639.
      View in: PubMed
    3. Hamouda D, Nascimento FA, Weathers SP, Kumar VA. Stroke-like migraine attacks after radiation therapy (SMART) syndrome. Arq Neuropsiquiatr. 2019 Mar; 77(3):215. PMID: 30970135.
      View in: PubMed
    4. Weathers SP, Epner DE. Rookie. J Clin Oncol. 2019 Mar 20; 37(9):751-753. PMID: 30742562.
      View in: PubMed
    5. Harrison RA, Nam JY, Weathers SP, DeMonte F. Intracranial dural, calvarial, and skull base metastases. Handb Clin Neurol. 2018; 149:205-225. PMID: 29307354.
      View in: PubMed
    6. Weathers SS, Gilbert MR. Toward Personalized Targeted Therapeutics: An Overview. Neurotherapeutics. 2017 04; 14(2):256-264. PMID: 27995437.
      View in: PubMed
    7. Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Kerrigan BCP, Heimberger AB. Tumor Vaccines for Malignant Gliomas. Neurotherapeutics. 2017 04; 14(2):345-357. PMID: 28389997.
      View in: PubMed
    8. Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, Verhaak RG, Hohl RJ, Barger GR, Reddy SK, Heimberger AB. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016 Oct 25; 7(43):69466-69478. PMID: 27579614.
      View in: PubMed
    9. Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol. 2016 09; 129(3):487-494. PMID: 27406589.
      View in: PubMed
    10. Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66. PMID: 27370400.
      View in: PubMed
    11. Gatson NT, Weathers SP, de Groot JF. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. CNS Oncol. 2016; 5(1):11-26. PMID: 26670466.
      View in: PubMed
    12. Weathers SP, de Groot J. VEGF Manipulation in Glioblastoma. Oncology (Williston Park). 2015 Oct; 29(10):720-7. PMID: 26470893.
      View in: PubMed
    13. Weathers SP, Gilbert MR. Current challenges in designing GBM trials for immunotherapy. J Neurooncol. 2015 Jul; 123(3):331-7. PMID: 25577401.
      View in: PubMed
    14. Weathers SP, Gilbert MR. Advances in treating glioblastoma. F1000Prime Rep. 2014; 6:46. PMID: 24991423.
      View in: PubMed
    15. Weathers SP, de Groot J. Resistance to antiangiogenic therapy. Curr Neurol Neurosci Rep. 2014 May; 14(5):443. PMID: 24652451.
      View in: PubMed
    16. Weathers SP, Kotagal V, Bohnen NI, Chou KL. Risky driving and pedunculopontine nucleus-thalamic cholinergic denervation in Parkinson disease. Parkinsonism Relat Disord. 2014 Jan; 20(1):13-6. PMID: 24070538.
      View in: PubMed
    17. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 1-8.
    18. Advances in treating glioblastoma. F1000Prime Reports. 6.
    19. Immune checkpoint blockade as a potential therapeutic target. Neuro-Oncology. 18:1357-1366.
    20. VEGF manipulation in glioblastoma. ONCOLOGY (United States). 29:720-727.
    21. Toward Personalized Targeted Therapeutics. Neurotherapeutics. 1-9.
    22. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 7:69466-69478.
    WEATHERS's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description